Tofacitinib in anti-MDA5-positive dermatomyositis-associated interstitial lung disease: a new standard of care emerges

The management of anti-melanoma differentiation-associated gene 5-positive dermatomyositis with interstitial lung disease (MDA5+DM-ILD) has been a challenge for clinicians worldwide since its recognition in 2005 [1]. Characterised by rapidly progressive interstitial lung disease (RP-ILD), hypomathic myositis, ulcerating Gottron's rashes, and a high 6-month mortality rate, this rare and severe condition often leads to a race against time in the quest for effective treatment [2]. Japanese researchers previously conducted a multicentre prospective study evaluating an intensive initial treatment approach that combined three agents: tacrolimus (a calcineurin inhibitor (CNI)), high-dose glucocorticoids, and intravenous cyclophosphamide [3]. This “triple therapy” showed improved 6-month survival rates in patients with MDA5+DM-ILD. However, a subsequent, larger, real-world study by the same research group found conflicting results: the triple-combination therapy did not demonstrate survival advantages over simpler regimens using glucocorticoids alone or with a single immunosuppressant [4]. Consequently, the current management of this intractable disease remains largely empirical. The rarity and aggressive progression of the disease have posed substantial challenges for conducting clinical trials, leaving the optimal immunosuppressive regimen uncertain. The large cohort study reported by Wu and co-workers shows that tofacitinib improves 1-year survival versus calcineurin inhibitors in anti-MDA5-positive dermatomyositis with ILD, supporting its use as first-line therapy https://bit.ly/3FGs9d1